Response to 'Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives'.

Creator(s)

Priya Patel
J Steven Leeder, Children's Mercy HospitalFollow
Micheline Piquette-Miller
L Lee Dupuis

Document Type

Response or Comment

Publication Date

3-2018

Identifier

DOI: 10.1111/bcp.13487; PMCID: PMC5809359

Abstract

Comment on

• Aprepitant and fosaprepitant drug interactions: a systematic review. Patel P, Leeder JS, Piquette-Miller M, Dupuis LL.Br J Clin Pharmacol. 2017 Oct;83(10):2148-2162. doi: 10.1111/bcp.13322. Epub 2017 Jun 10.PMID: 28470980 Free PMC article. Review.
• Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives. Bailard N, Rebello E.Br J Clin Pharmacol. 2018 Mar;84(3):602-603. doi: 10.1111/bcp.13472. Epub 2017 Dec 19.PMID: 29266364 Free PMC article. No abstract available.

Journal Title

British journal of clinical pharmacology

Volume

84

Issue

3

First Page

604

Last Page

604

MeSH Keywords

Aprepitant; Contraceptive Agents; Humans; Morpholines; Nausea

PubMed ID

29315725

Keywords

aprepitant; drug-drug interactions; fosaprepitant

Recommended Citation

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Response to 'Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives'. Br J Clin Pharmacol. 2018;84(3):604. doi:10.1111/bcp.13487